Articles: chronic.
-
Cancer Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMPURPOSE: Lymphoproliferative disorders(LPD) are common in immunosuppressed patients and in patients with connective tissue disorders(CTD). There is increased risk in Sjögren's syndrome(SS) and moderate risk in systemic lupus erythematosis(SLE). ⋯ The following authors have nothing to disclose: Shraddha Goyal, Adnan Abbasi, Pratibha Kaul, Fatme AllamNo Product/Research Disclosure Information.
-
Pleural CasesSESSION TYPE: Case ReportsPRESENTED ON: Sunday, March 23, 2014 at 09:00 AM - 10:00 AMINTRODUCTION: Sarcoidosis is a chronic multi-system disorder of unknown etiology characterized by granulomatous inflammation. Commonly involved organs include lymph nodes, lungs, skin, eyes and heart. Pulmonary involvement is manifested as hilar or mediastinal lymphadenopathy with parenchymal opacities. Pleural effusion and underlying pleural involvement with sarcoidosis is uncommon and is seen in less than 2% of the cases of pulmonary sarcoidosis. We present one of such case. ⋯ The following authors have nothing to disclose: Deepankar Sharma, Joshua RubenfeldNo Product/Research Disclosure Information.
-
Slide PresentationsPRESENTED ON: Monday, March 24, 2014 at 09:00 AM - 10:00 AMPURPOSE: Biomass smoke exposure is a risk factor for developing chronic obstructive pulmonary disease (COPD). Little is currently known concerning clinical differences between COPD due to tobacco and to biomass smoke. The purpose of this study was to search for clinical differences between both types of disease ⋯ Pilar Sanjuán: Consultant fee, speaker bureau, advisory committee, etc.: Almirall, Astra-Zeneca, Boehringer-Ingelheim Rafael Golpe: Consultant fee, speaker bureau, advisory committee, etc.: Novartis, GSK, Astra-Zeneca, Boehringer-Ingelheim, Almirall Luis Pérez-de-LLano: Grant monies (from industry related sources): Almirall, Consultant fee, speaker bureau, advisory committee, etc.: Almirall, Novertis, Astra-Zeneca, Boehringer-Ingelheim, GSK, Menarini Esteban Cano: Consultant fee, speaker bureau, advisory committee, etc.: GSK Olalla Castro-Añon: Consultant fee, speaker bureau, advisory committee, etc.: NovartisNo Product/Research Disclosure Information.
-
Non-invasive ventilation (NIV) is an evidence-based treatment of acute respiratory failure and can be helpful to reduce morbidity and mortality. In Germany national S3 guidelines for inhospital use of NIV based on a large number of clinical trials were published in 2008; however, only limited data for prehospital non-invasive ventilation (pNIV) and hence no recommendations for prehospital use exist so far. ⋯ Prehospital NIV in Germany was used by only one third of all respondents by the end of 2008. Based on the clinical data a growing application for pNIV is expected. Controlled prehospital studies are needed to enunciate evidence-based recommendations for pNIV.
-
BronchiectasisSESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: Evaluation of morbidity and risk factors for mortality in hospitalized patients with acute exacerbation of bronchiectasis. ⋯ The following authors have nothing to disclose: Maria João Oliveira, Daniel Vaz, Daniel Coutinho, Margarida Dias, Maria do Céu BritoNo Product/Research Disclosure Information.